ELAHERE has a well-established safety profile to help YOU support your patients through treatment
Adverse REACTIONS reported in ≥10% of patients receiving ELAHERE in SORAYA1
Adverse reaction (N=106)1
*Blurred vision includes vision blurred, vitreous floaters, visual acuity reduced, diplopia, presbyopia, accommodation disorder, visual impairment, and refraction disorder.1
†Keratopathy includes corneal disorder, corneal epithelial microcysts, corneal epithelial defect, keratitis, keratopathy, corneal deposits, and punctate keratitis.1
‡Dry eye includes dry eye and lacrimation increased.1
§Eye pain includes eye pain and ocular discomfort.1
¶Fatigue includes fatigue and asthenia.1
#Abdominal pain includes abdominal pain, abdominal pain upper, abdominal pain lower, abdominal discomfort.1
**Dyspnea includes dyspnea and exertional dyspnea.1
Dosage delays of ELAHERE due to an AR occurred in 39% of patients. ARs that required dosage delays in ≥3% of patients included1:
- Blurred vision (15%)
- Keratopathy (11%)
- Neutropenia (6%)
- Dry eye (5%)
- Cataracts (3%)
- Increased gamma-glutamyl transferase (3%)
Clinically relevant ARs occurring in <10% of patients who received ELAHERE in SORAYA included1:
- Infusion-related reactions/hypersensitivity (9%)
- Pneumonitis (8%)
- Uveitis (1%)
Dose reductions of ELAHERE due to an AR occurred in 20% of patients1
- ARs that required dose reductions in ≥3% of patients included blurred vision (9%) and keratopathy (7%)
Serious ARs occurred in 31% of patients. The most common (≥2%) serious ARs were1:
- Intestinal obstruction (8%)
- Ascites (4%)
- Infection (3%)
- Pleural effusion (3%)
Permanent discontinuation due to ARs occurred in 11% of patients1
- The most common (≥2%) ARs leading to permanent discontinuation were intestinal obstruction (2%) and thrombocytopenia (2%)
- One patient (0.9%) permanently discontinued ELAHERE due to visual impairment (unilateral decrease to BCVA ≤20/200 that resolved to baseline after discontinuation)
The median duration of treatment was 4.2 months (range: 0.7 to 13.3)1
AR=adverse reaction; BCVA=best corrected visual acuity.
Laboratory abnormalities in SORAYA
Select laboratory abnormalities ≥10% for all grades or ≥2% for Grades 3-4 in patients who received ELAHERE
Laboratory abnormalities for ELAHERE
ALT=alanine aminotransferase; AST=aspartate aminotransferase.
*The denominator used to calculate the rate varied from 98 to 101 based on the number of patients with a baseline value and at least 1 posttreatment value.1
Resources for treatment
From eye care to access and reimbursement, information is available to support your patients and your practice.
How dose modifications can help
Dose modifications can help manage adverse reactions and keep patients on treatment.